GSK says GSK3036656 demonstrated early bactericidal activity in Phase IIa study

GSK plc announced "positive" results from a Phase IIa study demonstrating that GSK3036656, a first-in-class investigational antitubercular agent, was well tolerated and showed early bactericidal activity with a low, once-daily oral dose after 14 days of treatment in participants with drug-susceptible pulmonary tuberculosis. "These results demonstrate the potential for GSK3036656 to be a component of simpler treatment regimens in the future which could help address the TB epidemic," the company stated. A selection of these data was presented in an oral late breaker session at the Union World Conference on Lung Health on November 11. David Barros-Aguirre, Head of Global Health Medicines R&D, GSK, said: "Existing treatments for TB can be complicated, of long duration and have serious side effects which significantly impact the lives of patients with TB around the world. Today’s encouraging data provide a good foundation from which to investigate GSK3036656 in different combinations in Phase IIb/c studies, with the aim of contributing to shorter, simpler and better tolerated treatment regimens for patients with TB."